


CANCER GENOMICS & PROTEOMICS

Volume 11, Number 3, May-June 2014

ISSN (online): 1790-6245



CANCER GENOMICS & PROTEOMICS

Online ISSN: 1790-6245

Editor-in-Chief:

ARUN SETH, *Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada*

Managing Editor:

J.G. DELINASIOS, *International Institute of Anticancer Research (IAR), Kapandriti, Attiki, Greece*

Editorial Board

L. A. Aaltonen, *Helsinki, Finland*

R. Abagyan, *La Jolla, CA, USA*

F. Ahmed, *Greenville, NC, USA*

D.-T. Bau, *Taiwan, ROC*

B. F. C. Clark, *Aarhus, Denmark*

R. Clarke, *Washington, DC, USA*

T. Efferth, *Mainz, Germany*

J. A. Fernandez-Pol, *Chesterfield, MO, USA*

C.V. Forst, *New York, NY, USA*

D. S. Gerhard, *Bethesda, MD, USA*

T.R. Golub, *Cambridge, MA, USA*

J. Gordon, *Philadelphia, PA, USA*

J. W. Gray, *Portland, OR, USA*

C.-H. Heldin, *Uppsala, Sweden*

J. D. Hoheisel, *Heidelberg, Germany*

R. P. Huang, *Norcross, GA, USA*

T. H. M. Huang, *San Antonio, TX, USA*

S. C. Jhanwar, *New York, NY, USA*

W.G. Jiang, *Cardiff, UK*

V. C. Jordan, *Washington, DC, USA*

J. Ju, *Stony Brook, NY, USA*

A. Kallioniemi, *Tampere, Finland*

O. P. Kallioniemi, *Turku, Finland*

K. Khalili, *Philadelphia, PA, USA*

D. G. Kieback, *Riesa (Dresden), Germany*

S. D. Kottaridis, *Athens, Greece*

Y. T. Kwon, *Seoul, Republic of Korea*

B. Léylund-Jones, *Sioux Falls, SD, USA*

P. Lichter, *Heidelberg, Germany*

A. Lindblom, *Stockholm, Sweden*

G. Lubec, *Vienna, Austria*

J. Lyons-Weiler, *Pittsburgh, PA, USA*

P. J. McCormick, *Rensselaer, NY, USA*

J. D. Minna, *Dallas, TX, USA*

F. Mitelman, *Lund, Sweden*

C. Nicot, *Kansas City, KS, USA*

L. O'Driscoll, *Dublin, Ireland*

I. Pastan, *Bethesda, MD, USA*

C. D. Platsoucas, *Norfolk, VA, USA*

J. Quackenbush, *Boston, MA, USA*

J. S. Rader, *Milwaukee, WI, USA*

R. H. Reeves, *Baltimore, MD, USA*

K. L. Reichelt, *Oslo, Norway*

T. Ried, *Bethesda, MD, USA*

G. Rimbach, *Kiel, Germany*

K. D. Rodland, *Richland, WA, USA*

C. Sansom, *London, UK*

N. A. Saunders, *Queensland, Australia*

B.W. Schäfer, *Zurich, Switzerland*

J. Schneider, *Madrid, Spain*

O. J. Semmes, *Norfolk, VA, USA*

G. V. Sherbet, *Newcastle-upon-Tyne, UK*

S. Smith, *Duarte, CA, USA*

J. C. Strefford, *Southampton, UK*

J. M. Trent, *Phoenix, AZ, USA*

G. Tsangaris, *Athens, Greece*

L.-C. Tsui, *Hong Kong, Hong Kong*

G. F. Vande Woude, *Grand Rapids, MI, USA*

D. K. Watson, *Charleston, SC, USA*

U.H. Weidle, *Penzberg, Germany*

A. T. Yeung, *Philadelphia, PA, USA*

H. Zhang, *New Haven, CT, USA*

Editorial Office: International Institute of Anticancer Research

1st km Kapandritiou-Kalamou Rd.,

P.O. Box 22, Kapandriti, Attiki 19014, Greece.

Tel: +30 22950 52945, Fax: +30 22950 53389

E-mails:

journals@iiar-anticancer.org (Editorial Office)

editor@iiar-anticancer.org (Managing Editor)

www.iiar-anticancer.org

<http://cgp.iiarjournals.org>

Editorial Policy. CANCER GENOMICS & PROTEOMICS (CGP) welcomes the submission of high quality original articles and reviews on all aspects of the application of genomic and proteomic technologies to experimental and clinical cancer research. The Journal's scientific spectrum includes: (a) molecular causes of carcinogenesis, cancer progression and metastasis; (b) structural and functional aspects of genes in the cancer cell; (c) advances in genomic and proteomic technologies applicable to cancer research; (d) anticancer drug design and drug development.

CGP will also accept abstracts and proceedings of scientific meetings for publication, following consideration and approval by the Editorial Board.

A main aim of CGP is to ensure the prompt and confidential review, and rapid publication of original works and reviews, generally within 1-2 months from acceptance.

For more information about CANCER GENOMICS & PROTEOMICS, IAR and the Conferences, please visit the IAR website: www.iiar-anticancer.org

Publication Data: CANCER GENOMICS & PROTEOMICS (CGP) is published bimonthly online-only and open access by the International Institute of Anticancer Research. Each annual volume comprises of six issues. Annual Author and Subject Indexes are included in the sixth issue of each volume. CANCER GENOMICS & PROTEOMICS Vol. 1 (2004) and onwards appears online with Stanford University HighWire Press. All published articles are deposited in PubMed Central.

Open Access Policy: CGP appears bimonthly as an online-only open access journal through the Stanford University HighWire Press. Upon acceptance, Authors will be asked to pay an online publication fee of Euro 700.00 for articles up to 6 online pages (including figures and tables). Each additional excess page will be charged Euro 50.00. Color will not be charged. Authors from developing countries may apply for a 25% discount after the acceptance of their paper. CGP online will keep the volume and issue numbers, as well as page numbering.

Copyright: Authors retain copyright. The unrestricted *non-commercial* use, distribution and reproduction in any medium of CGP articles for academic reasons is allowed, provided that the original work is properly cited. The Authors grant the permanent right to the publisher to use any articles published in this journal without any restriction, including academic advertising purposes. PDF, XML and HTML files of all articles published in CGP are the property of the publisher.

Manuscripts and correspondence should be addressed to: Dr. John G. Delinasios, Managing Editor, Editorial Office, Cancer Genomics & Proteomics, 1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389, e-mail: editor@iiar-anticancer.org

Manuscripts from North America may be sent to the Editor-in-Chief, Prof. A. Seth, CGP, Laboratory of Molecular Pathology, Sunnybrook Research Institute, University of Toronto, 2075 Bayview Avenue, Room S112a, Toronto, ON, Canada M4N 3M5. Fax: 416 480 5737. E-mail: genomics.proteomics@utoronto.ca

The Editors and Publishers of CANCER GENOMICS & PROTEOMICS accept no responsibility for the opinions expressed by the contributors or for the content of advertisements appearing therein.

Copyright© 2014, International Institute of Anticancer Research (Dr. John G. Delinasios), All rights reserved

PHOTOCOMPOSITION BY IAR



9th INTERNATIONAL CONFERENCE OF ANTICANCER RESEARCH

6-10 October 2014,
Porto Carras, Sithonia, Greece

www.iar-anticancer.org/conference

Information

Under the auspices of:

- The Union for International Cancer Control (UICC)
- The Asian and Pacific Federation of Clinical Biochemistry (APFCB)
- The Asian Pacific Organization for Cancer Prevention (APOCP)
- The Austrian Society for Radiation Oncology (ÖGRO)
- The European Group on Tumor Markers (EGTM)
- The Hungarian Society of Epidemiology
- The International Cancer Microenvironment Society (ICMS)
- The International Geriatric Radiotherapy Group (IGRG)
- The International Institute of Anticancer Research (IIAR)
- The International Society for Biological and Environmental Repositories (ISBER)
- The International Society of Oncology and Biomarkers (ISOBM)
- The Italian Society of Uro-Oncology (SIUrO)
- The Latinamerican and Caribbean Society of Medical Oncology (SLACOM)
- The Lithuanian Society of Radiation Oncology (LSRT)
- The North-Eastern German Society of Gynecological Oncology (NOGGO)
- The Polish Society of Radiation Oncology (PSTRO)
- The Portuguese Society of Radiotherapy - Oncology (SPRO)
- The Society of Biotherapeutic Approaches, Japan
- The Szeged Foundation for Cancer Research, Hungary
- The Turkish Society for Electron Microscopy (TSEM)

Supported by:

- The International Institute of Anticancer Research



Deadline for registration: September 26, 2014.

Deadline for submission of abstracts: August 10, 2014.

Dates and Venue

The 9th International Conference of Anticancer Research will be held at the Porto Carras Grand Resort, Sithonia, Halkidiki, Greece, from 6 to 10 October, 2014.

General Policy

The purpose of the Anticancer Research Conferences is to exchange scientific information worldwide and to discuss recent advances in both broad and specialized areas of experimental and clinical cancer research. International Scientific and Medical Societies are invited to participate in the Conference by organizing specialized sessions. This initiative presents a forum for inter-Society communication allowing the organization and coordination of international activities on cancer.

Special sessions will be devoted to the discussion and arrangement of international cooperation projects and activities, encompassing the aims of the International Institute of Anticancer Research.

The Conference is organized and supported by the International Institute of Anticancer Research.

The Scientific Program will comprise of oral (10, 15, 30 or 40 minutes) and poster presentations. Both overviews and original works will be presented. Each oral presentation will be allocated a five-minute discussion-time. Six conference rooms will be used simultaneously. Posters will be exhibited for 1-2 days. Projection facilities for PowerPoint presentations will be provided.

The Conference website (www.iar-anticancer.org/conference) will be consistently updated announcing new titles of accepted abstracts, new special symposia and social events.

Organizing Committee

- P.A. Abrahamsson**, Malmö, Sweden
N. Agnantis, Ioannina, Greece
F.E. Ahmed, Greenville, NC, USA
C. Alexiou, Erlangen, Germany
L. Amaral, Lisbon, Portugal
F.L. Ampil, Shreveport, LA, USA
R. Andersson, Lund, Sweden
S. Arbak, Istanbul, Turkey
V. Barak, Jerusalem, Israel
D.-T. Bau, Taichung, Taiwan
G. Bauer, Freiburg, Germany
A. Bishayee, Signal Hill, CA, USA
R. Bjerkvig, Bergen, Norway
G. Broich, Monza, Italy
C. Carlberg, Kuopio, Finland
J. Carlsson, Uppsala, Sweden
D. Characiejus, Vilnius, Lithuania
C.J. Chen, Taipei, Taiwan
G. Ciarimboli, Münster, Germany
B.F.C. Clark, Aarhus, Denmark
R. Clarke, Washington, DC, USA
P. Coltery, Bastia, France
H. Cross, Vienna, Austria
M. De Braekeleer, Brest, France
K. De Meirleir, Brussels, Belgium
A.Z. Dudek, Chicago, IL, USA
A. Dutour, Lyon, France
P. Dziegiel, Wrocław, Poland
T. Efferth, Mainz, Germany
W. Engström, Uppsala, Sweden
M. Eskelinen, Kuopio, Finland
J.A. Fernandez-Pol, Chesterfield, MO, USA
A. Fields, Jacksonville, FL, USA
M. Friedrich, Krefeld, Germany
R. Friedrich, Hamburg, Germany
H.-J. Gabius, Munich, Germany
R. Ganapathi, Charlotte, NC, USA
A.F. Gazdar, Dallas, TX, USA
V. Gebbia, Palermo, Italy
J.W. Greiner, Bethesda, MD, USA
F. Guadagni, Rome, Italy
C. Hastie, Guildford, Surrey, UK
J. Hau, Copenhagen, Denmark
R. Hoffman, San Diego, CA, USA
S. Holdenrieder, Bonn, Germany
T. Isbir, Istanbul, Turkey
S. Jhanwar, New York, NY, USA
M. Jhanwar-Uniyal, New York, NY, USA
B. Kaina, Mainz, Germany
E. Kandil, New Orleans, LA, USA
Y. Keisari, Tel Aviv, Israel
D.G. Kieback, Riesa (Dresden), Germany
I. Kiss, Pécs, Hungary
R. Klapdor, Hamburg, Germany
R. Knecht, Hamburg, Germany
M. Kohonen-Corish, Sydney, NSW, Australia
M. Koutsilieris, Athens, Greece
K. Kubota, Mibu, Tochigi, Japan
S. Kumar, Manchester, UK
P.M. Kumar, Manchester, UK
O.D. Laerum, Bergen, Norway
S.A. Lamprecht, Beer-Sheva, Israel
W. Lichtenegger, Berlin, Germany
D. Lincoln, Chapel Hill, QLD, Australia
B. Littlefield, Andover, MA, USA
F. Lumachi, Padova, Italy
S. Mitra, Galveston, TX, USA
R. Molina, Barcelona, Spain
J. Molnár, Szeged, Hungary
N. Motohashi, Tokyo, Japan
R.M. Nagler, Haifa, Israel
R. Nano, Pavia, Italy
N. Nguyen, Tucson, AZ, USA
C. Nicolini, Genova, Italy
C. Pace-Asciak, Toronto, ON, Canada
S. Pathak, Houston, TX, USA
G.J. Pilkington, Portsmouth, UK
C.D. Platsoucas, Norfolk, VA, USA
A. Polliack, Jerusalem, Israel
J. Reichrath, Homburg/Saar, Germany
D.A. Ribeiro, Santos, SP, Brazil
M. Rigaud, Limoges, France
F.M. Robertson, Houston, TX, USA
M. Roselli, Rome, Italy
G.R. Rutteman, Utrecht, Netherlands
C. Sansom, London, UK
S. Sarkar, Boston, MA, USA
A. Schauer, Göttingen, Germany
D. Schiffer, Vercelli, Italy
J. Schneider, Alcorcón (Madrid) Spain
M. Schneider, Wuppertal, Germany
O.J. Semmes, Norfolk, VA, USA
A. Seth, Toronto, ON, Canada
G. Sica, Rome, Italy
J. Slansky, Denver, CO, USA
K. Smetana, Prague, Czech Republic
S.S. Smith, Duarte, CA, USA
R.M. Snapka, Columbus, OH, USA
D.D. Spyropoulos, Charleston, NC, USA
J. Sterling, Nashville, TN, USA
T. Stigbrand, Umeå, Sweden
K. Syrjänen, Helsinki, Finland
R.T. Todorova, Sofia, Bulgaria
O. Topolcan, Pilsen, Czech Republic
G.C. Torre, Finale Ligure (SV), Italy
V. Treska, Pilsen, Czech Republic
M. de L.G. Trigo, Porto, Portugal
G. Tsangaris, Athens, Greece
E. Vairaktaris, Athens, Greece
D. Vesely, Tampa, FL, USA
D. Vetvicka, Prague, Czech Republic
J.K. Vishwanatha, Fort Worth, TX, USA
G. Vollmer, Dresden, Germany
A. Wani, Columbus, OH, USA
I.P. Witz, Tel Aviv, Israel
Y. Yen, Duarte, CA, USA
C.H. Yip, Petaling Jaya, Malaysia
O. Zoras, Heraklion, Greece

Scientific Program

Experimental Research Sessions

1. Oncogenes; tumor suppressor genes; growth factors; signal transduction.
2. Molecular and cellular biology of cancer.
3. Cancer stem cells.
4. Cancer cell differentiation.
5. Cancer genomics. Microarray technology.
6. Cancer proteomics. Metabolomics.
7. Cancer systems biology and signaling.
8. Cancer metabolism and autophagy.
9. Reactive oxygen/nitrogen species and cancer.
10. MicroRNAs in cancer.
11. Invasion and metastasis.
12. Cytogenetics and genetics.
13. Epigenetics.
14. Tumor angiogenesis and anti-angiogenesis.
15. Multi-drug and drug resistance. Mechanisms and reversal.

16. Apoptosis.
17. Tumor microenvironment; cell-cell interactions; adhesion; stroma; cancer-associated fibroblasts.
18. Carcinogenesis. Viral oncogenesis.
19. New anticancer agents.
20. Natural products in cancer drug development.
21. Experimental chemotherapy.
22. Immunobiology of cancer.
23. Gene therapy.
24. Aging and cancer.

Clinical Research Sessions

25. Diagnosis and prognosis of cancer.
26. Cancer surgery.
27. Serum markers in diagnosis and therapy.
28. Clinical chemotherapy.
29. Immunotherapy; biotherapy; vaccines.
30. Hormone therapy.

31. Radiotherapy.
32. Hyperthermia.
33. Personalized medicine in cancer.
34. Advances in breast cancer.
35. Advances in gynecological cancer.
36. Advances in prostate cancer.
37. Advances in neurooncology.
38. Advances in colorectal cancer.
39. Advances in head and neck cancer.
40. Advances in stomach and esophageal cancer.
41. Advances in hemato-oncology.
42. Melanoma: New therapies and biomarkers.
43. Chemoprevention. Environmental exposure and cancer risk.
44. Epidemiology.
45. Nutrition and cancer. Nutritional aspects of cancer prevention.

Special Symposia

1. PKC signaling in cancer. Organized by A.P. Fields (Jacksonville, FL, USA)-(Oct. 6)
2. Hepatocellular carcinoma. Organized by Keichi Kubota (Mibu, Tochigi, Japan)-(Oct. 8)
3. Cancer Prevention in Asia Pacific Countries. Organized by C.H. Yip (Petaling Jaya, Malaysia), C.J. Chen (Taipei, Taiwan) (APOCP)-(Oct. 9)
4. Invasion and carcinomas of the GI tract. Organized by O.D. Laerum (Bergen, Norway)-(Oct. 8)
5. Toxicology and cancer aetiology. Organized by C.H. Yip (Petaling Jaya, Malaysia), C.J. Chen (Taipei, Taiwan) (APOCP)-(Oct. 9)
6. Genomic instability and cancer (DNA repair). Organized by A. Wani (Columbus, OH, USA)-(Oct. 6)
7. Drug resistance in cancer and targeting DNA repair pathways. Organized by S. Mitra (Galveston, TX, USA), B. Kaina (Mainz, Germany)-(Oct. 8)
8. Image-guided radiotherapy. Organized by Nam Nguyen (Tucson, AZ, USA)-(Oct. 7)
9. Circulating tumor cells. Organized by M. Rigaud (Limoges, France)-(Oct. 6)
10. Cancer stem cells. Organized by M. Jhanwar-Uniyal (New York, NY, USA), F. Guadagni (Rome, Italy)-(Oct. 7)
11. Regulation of efflux pumps of mdr cancer by phenothiazine derivatives and natural products. Organized by L. Amaral (Lisbon, Portugal), J. Molnár (Szeged, Hungary)-(Oct. 10)
12. Drug delivery. Organized by D. Vetricka (Prague, Czech Republic)-(Oct. 6)
13. Genomics and clinical management of ovarian cancer. Organized by R. Ganapathi (Charlotte, NC, USA)-(Oct. 6)
14. New insights in prostate cancer. Organized by C. Aukim-Hastie (Guildford, Surrey, UK)-(Oct. 6)
15. Hox genes in cancer. Organized by C. Aukim-Hastie (Guildford, Surrey, UK)-(Oct. 7)
16. Application of RT-qPCR in Biomedicine. Organized by F.E. Ahmed (Greenville, NC, USA)-(Oct. 7)
17. Vitamin D and Cancer. Organized by M. Friedrich (Krefeld, Germany), J. Reichrath (Homburg/Saar, Germany)-(Oct. 8)
18. Biobanks: A research infrastructure for the future of translational and clinical research. ISBER Symposium. Organized by F. Betsou (Luxembourg), Guadagni (Rome, Italy), M. Roselli (Rome, Italy)-(Oct. 8)
19. New insight into brain tumors. Organized by G. Sica (Rome, Italy), M. Jhanwar-Uniyal (New York, NY, USA)-(Oct. 10)
20. Micro RNAs in cancer. Organized by A. Seth (Toronto, ON, Canada)-(Oct. 10)
21. Next generation sequencing for cancer drug development and diagnostics. Organized by A. Seth (Toronto, ON, Canada)-(Oct. 8)
22. Transporters as mediators of uptake of chemotherapeutic drugs in target and non-target cells. Organized by G. Ciarimboli (Münster, Germany)-(Oct. 10)
23. Metal-based drugs and cancer. Organized by P. Collery (Bastia, France)-(Oct. 10)
24. Brain cancer treatment: Epigenetic networks. Organized by R. Nano and E. Benericetti (Pavia, Italy)-(Oct. 8)
25. Targeting the tumour microenvironment. Organized by I. Witz, Y. Keisari (Israel)-(Oct. 6)
26. Breast Cancer: Pathology and Imaging. Organized by N.J. Agnantis (Ioannina, Greece)-(Oct. 7)
27. The sugar code in tumor biology/pathology: Principles and Examples. Organized by H.-J. Gabius (München, Germany)-(Oct. 6)
28. Microenvironmental heterogeneity of brain tumours: Dynamic topographical changes and adaptation to therapies. Organized by G.J. Pilkington (Portsmouth, UK)-(Oct. 7)
29. Alternative and complementary medicine in cancer treatment. Organized by S. Pathak (Houston, TX, USA)-(Oct. 6)
30. Natural products in cancer drug development. Organized by B. Littlefield (Andover, MA, USA)-(Oct. 9)

Publications

Abstracts of all contributed papers will be published in a special issue of ANTICANCER RESEARCH, which will be distributed to registrants during the Conference, as well as to all subscribing libraries and indexing services (print and online through the Stanford University HighWire Press). After recommendation by the Organizing Committee, selected contributions will be invited as complete original papers or reviews to be submitted for publication in ANTICANCER RESEARCH. Paper submissions will also be welcome during the Conference.

Abstracts (titles and authors) will be announced in www.iar-anticancer.org/conference upon acceptance. The final conference program will be publicised on September 10, 2014.

Registration

- **Registration is required of all participants.**
- **Registration deadline:** 26 September, 2014.
- **Deadline for submission of abstracts:** 10 August, 2014.
- **Registration fee:** EURO 260.00; Students, EURO 100.00; accompanying person, EURO 100.00 (each); Children, no fee.
- The registration fee for the Conference participants partially covers: attendance at the scientific sessions; all Conference material and documentation (final program, list of participants, book of Abstracts, Conference folder, Certificate of attendance and registration badge) from the Conference Secretariat; participation in all social events (social dinners, music recital, coffee breaks, closing gala dinner), and conference gifts.
- The registration fee for accompanying persons covers: participation in all social events; eligibility for special accommodation fees (the same offer applies to Conference participants).
- The registration fee for the Members of the auspicious societies is waived.
- Registration will be regarded as final only after all forms and registration plus accommodation fees have been received by the Editorial Office of Anticancer Research.

Accommodation

Hotel reservation requests should be submitted directly to the Editorial Office of Anticancer Research. Porto Carras Grand Resort (★★★★★) is located in a beautiful, peaceful setting by the sea and will provide excellent service and quality half-board accommodation for all participants.

- Accommodation fees:
 - Double room: EURO 132.00 for 2 persons, per night.
 - Single room: EURO 98.00 per person, per night.
 - Children 2-12 years old as 3rd person in double room: EURO 35.00.
 - Triple room: EURO 180.00 for 3 persons, per night.The fee covers: accommodation in A (★★★★★) type rooms (bath, balcony, radio, TV, telephone), breakfast, dinner and transportation from and to the Airport of Thessaloniki on October 5 and October 11, 2014, respectively.
- Service hours: Breakfast (buffet): 7.30 – 10.00 a.m.; Dinner (formal club style) 19.00 – 22.30 p.m.; Self-service restaurant for lunch: 12.30 – 14.00 p.m.
- Accommodation requests are valid if made through the official conference Registration Form. For accommodation & registration to be secured all fees need to have been paid in advance.
- Cancellations: Abstract and registration plus accommodation fees will be returned if participation is cancelled before August 10, 2014. No refunds will be offered past this date.

Travel Arrangements

The Conference will officially commence on the morning of October 6, 2014. Therefore, participants should preferably arrive on October 5, 2014. The conference will conclude with the closing gala dinner on October 10, 2014. Participants are advised to finalize their travel plans at the earliest possible date. Details of date, flight number and time of arrival at Thessaloniki Airport should be given to the Editorial Office not later than September 26, 2014.

Aegean Airlines: www.aegeanair.com

Olympic Airways: www.olympicairlines.com

Airport – Hotel Transportation

Shuttle buses will provide transportation from Thessaloniki Airport to the Hotel only on Sunday, October 5, 2014, and from the Hotel to the airport only on Saturday, October 11, 2014. Participants will be welcomed at the airport by a conference representative. Participants arriving on days other than October 5 or departing on days other than October 11 will have to hire a taxi (50 min, Euro ~120) at their own expense.

Instructions for Submitting an Abstract

1. Only abstracts containing new results (original research work or overviews) will be accepted. Abstracts should clearly and adequately describe the objectives and results of the research. All abstracts must be submitted in English.
2. All abstracts need to be accompanied by a completed Conference Registration Form made out in the name of the Author presenting the paper.
 - a. Each abstract should include a title (in capital letters), names of all authors (with the name of the author who will be presenting the paper underlined), as well as complete address(es).
 - b. Two types of abstracts may be submitted:
 - Short abstract, not exceeding 300 words.
 - Long abstracts not exceeding 1500 words, with 1-2 figures or tables (max size 8 cm width x 12 cm height), including abstract, introduction, materials and methods, results, discussion, acknowledgements, references. Color figures will be charged 180.00 EURO per page.
 - c. Careful typing and proof-reading are essential.
 - d. Abstract forms will not be provided.
3. Abstracts and a completed Conference Registration Form should be sent to: Dr. John G. Delinasios, International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd, P.O. Box 22, Kapandriti 19014, Greece. E-mail: conference@iicar-anticancer.org.

**Abstracts must arrive at our offices
by August 10, 2014, at the latest.**

4. A reply (regarding decision, acceptance or revision) will reach the author within 5-12 days from submission.

Instructions for Poster Presentations

Abstracts scheduled for presentation in poster sessions will be grouped by topic, numbered and listed in the program, and published in the Abstract Book, as well as in ANTICANCER RESEARCH. Posters will be exhibited for 1-2 days and program listings will specify the time for poster discussion.

The original abstract of each poster presentation should arrive by August 10, 2014, at the latest at our offices. For the preparation of the abstract, please follow the Instructions for Submitting an Abstract.

The poster board surface area is 0.64 m² [0.8 m (31.5 inches) high and 0.8 m (31.5 inches) wide]. Poster presentations should include: title, authors, institutional affiliation, abstract, short introduction, methods, results, discussion, references and conclusion.

Social Program

- Opera Evening.
DIMITRA THEODOSSIOU, soprano.
DIMITRIS YAKAS, piano.
Arias by Verdi, Puccini, Mascagni.
No fee (date to be announced).
- Classical Guitar Recital of George Tossikian. No fee (date to be announced).
- Concert of the composer George Varsamakis (piano) and the Crescendo String Quartet. Classical and modern music and songs.
- Greek traditional dances. No fee (date to be announced).
- Closing ceremony and Gala Dinner on Friday, October 10, 2014. No fee.
- A special program of visits to archaeological sites, visits to museums, excursions, and tours will also be available.
The program includes: The Holy Monasteries of Mount Athos (excursion and cruise); Alexander the Great tour (Pella, Vergina, Veroia); Dion; Amphipolis, Filippi, Kavala; Thessaloniki tour, Byzantine and Archaeological Museums, etc. Tickets can be ordered at the desk of the Conference Secretariat.

Sithonia

Sithonia, the central peninsula of Chalkidiki, is varnished with unique, virgin bays and plenty of serene and natural beaches. The place that hosted both Aristotle and Alexander the Great has succeeded in keeping a low profile in mass tourism campaigns and maintaining its cultural uniqueness and natural beauty. Situated right next to Thessaloniki, voted best of the world places by National Geographic, it dazzles the international traveler with an interminable list of archaeological sights of great magnitude. The museum of Vergina hosts immaculate gold treasures from the burial site of King Philip II, Alexander the Great's father. The ancient Kavala aqueduct, the ancient theatre of Filippi, the archaeological areas of Vergina, Dion and Pella, and countless byzantine monuments and churches are only a few of the nearby sites that inspire a great historical time travel experience.

Weather

October is a very pleasant month in Sithonia, Greece. The average temperature is 24 °C (range 20-30 °C).

The Previous Conferences of Anticancer Research

	Location & Year	Number of Participants	Total Number of Papers	(Original / Reviews)
1st	Loutraki, 1985	450	285	(234 / 51)
2nd	Saronis, 1988	550	339	(299 / 40)
3rd	Marathon, 1990	580	332	(287 / 45)
4th	Crete, 1992	650	402	(347 / 55)
5th	Corfu, 1995	860	555	(460 / 95)
6th	Halkidiki, 1998	640	450	(405 / 45)
7th	Corfu, 2004	1,190	616	(552 / 64)
8th	Kos, 2008	1,212	760	(692 / 68)



Porto Carras Grand Resort, Sithonia, Greece

9th INTERNATIONAL CONFERENCE OF ANTICANCER RESEARCH

6-10 October 2014, Porto Carras, Sithonia, Greece

www.iar-anticancer/conference

CONFERENCE REGISTRATION FORM

- Please reserve my place at the 9th International Conference of Anticancer Research.
- I shall be accompanied by adults and children.
(Please complete separate forms for each accompanying person.)
- I plan to present poster(s). Topic number
- I plan to present oral communication(s): minutes. Topic Number
- Abstract is attached. (Please follow the instructions for submitting an abstract).
- I shall require accommodation in single or double room;
Accommodation fees: Double room, EURO 132.00 for 2 persons per night; Single room, EURO 98.00 per person per night;
Children 2-12 years old, as 3rd person in the same room, EURO 35.00 (per child). Triple room, EURO 180.00 for 3 persons per night.
The fee covers accommodation in 5*-type rooms, breakfast, dinner, transportation from and to Thessaloniki Airport (5-11 October 14).
Registration fee: EURO 260.00; Students, EURO 100.00; Accompanying person, EURO 100.00; Children: No fee.
- Registration fee is enclosed. Accommodation fee for nights is also enclosed.
(Cheques should be made payable to Delinasios G.J. & CO G.P., Athens, Greece. Credit cards are NOT accepted.)
- Please send an invoice for EURO (and instructions for payment).
Please provide VAT number and billing address for European invoices.
- I am a student (certificate enclosed).
- I will require transportation between Thessaloniki Airport and the Porto Carras Hotels on October 5 and 11, 2014.
Time of my arrival: Flight no.: Time of my departure: Flight no.:
- Please enter my personal subscription to Anticancer Research/IN VIVO/2015,
at the special conference rate: online (EURO 200.00); print & online (EURO 300.00).

Title:
Name: Sex: male or female
Institution (or Company):
Address:
Tel: Fax: E-mail:

Deadline for registration: September 26, 2014.

Deadline for submission of abstracts: 10 August, 2014.

Please send completed form and Registration & Accommodation fees to:

Dr. John G. Delinasios, International Institute of Anticancer Research,
1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti 19014, Greece.

Tel. / Fax : +30 22950 53389; e-mail: conference@iiar-anticancer.org. Website: www.iar-anticancer.org/conference

Please photocopy for additional forms.



CANCER GENOMICS & PROTEOMICS

Print ISSN (2004-2012): 1109-6535
Online ISSN: 1790-6245

VOLUME 11, No 3
2014

Editorial Board

- A. Seth** Editor-in-Chief
Laboratory of Molecular Pathology, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre and University of Toronto, Toronto, Ontario, Canada
- J.G. Delinasios** Managing Editor and Executive Publisher
International Institute of Anticancer Research, Athens, Greece
- L.A. Aaltonen** Department of Medical Genetics, University of Helsinki, Finland
R. Abagyan The Scripps Research Institute, La Jolla, CA, USA
F. Ahmed Department of Radiation Oncology, East Carolina University School of Medicine, Greenville, NC, USA
D.-T. Bau Terry Fox Cancer Research Lab, China Medical University Hospital, Taichung, Taiwan
B.F.C. Clark Department of Molecular Biology, University of Aarhus, Denmark
R. Clarke Vincent T. Lombardi Cancer Center, Georgetown University School of Medicine, Washington, DC, USA
T. Efferth Department of Pharmaceutical Biology Institute of Pharmacy and Biochemistry, University of Mainz, Germany
J.A. Fernandes-Pol Metalloproteomics, LLC, Chesterfield, MO, USA
C.V. Forst Department of Genetics and Genomic Sciences, Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
D.S. Gerhard NIH / NCI, Office of Cancer Genomics, Bethesda, MD, USA
T.R. Golub Pediatric Oncology, Dana-Farber Cancer Institute, Cambridge, MA, USA
J. Gordon Department of Neuroscience, Center for Neurovirology, Temple University School of Medicine, Philadelphia, PA, USA
J.W. Gray OHSU Knight Cancer Institute, Biomedical Engineering, Portland, OR, USA
C.-H. Heldin Ludwig Institute for Cancer Research, Uppsala, Sweden
J.D. Hoheisel Deutsches Krebsforschungszentrum, Genome Research and Bioinformatics, Heidelberg, Germany
R.P. Huang RayBiotech, Inc., Norcross, GA, USA
T.H.M. Huang Department of Molecular Medicine/Institute of Biotechnology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA
S.C. Jhanwar Departments of Pathology and Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
W.G. Jiang Metastasis and Angiogenesis Research Group, Department of Surgery, Cardiff University School of Medicine, Cardiff, UK
V.C. Jordan Department of Oncology, Lombardi Comprehensive Cancer Center, Washington, DC, USA
J. Ju Translational Research Laboratories, State University of New York, School of Medicine, Stony Brook, NY, USA
A. Kallioniemi Laboratory of Cancer Genetics, Institute of Medical Technology, Tampere University Hospital, Finland
O.P. Kallioniemi Medical Biotechnology Group, VTT Technical Research Centre of Finland, Turku, Finland
K. Khalili College of Science and Technology, Center for Neurovirology and Cancer Biology, Temple University, Philadelphia, PA, USA
D.G. Kieback Department of Obstetrics and Gynecology, Elblandklinikum, Riesa (Dresden), Germany
S.D. Kottaridis Department of Virology, Hellenic Anticancer Institute, Athens, Greece
Y. T. Kwon Department of Biomedical Sciences, College of Medicine, Seoul National University, Seoul, Republic of Korea
B. Léylund-Jones Avera Cancer Institute, Sioux Falls, SD, USA
P. Lichter Deutsches Krebsforschungszentrum, Heidelberg, Germany
A. Lindblom Karolinska Hospital, Department of Molecular Medicine and Surgery, Stockholm, Sweden
G. Lubec Department of Pediatrics, University of Vienna, Austria
J. Lyons-Weiler Department of Pathology, Center for Oncology Informatics, University of Pittsburgh, PA, USA
P.J. McCormick The Center for Functional Genomics, Gen*NY*Sis Center for Excellence in Cancer Genomics, University of Albany, SUNY, Rensselaer, NY, USA
J.D. Minna Hamon Center for Therapeutic Oncology, University of Texas, Southwestern Medical Center at Dallas, TX, USA
F. Mitelman Department of Clinical Genetics, University Hospital, Lund, Sweden
C. Nicot Department of Microbiology, Immunology and Molecular Genetics, University of Kansas Medical Center, Kansas City, KS, USA

L. O'Driscoll	School of Pharmacy and Pharmaceutical Sciences, Trinity College, Dublin, Ireland
I. Pastan	Laboratory of Molecular Biology, NCI, NIH, Bethesda, MD, USA
C.D. Platsoucas	College of Sciences, Old Dominion University, Norfolk, VA, USA
J. Quackenbush	Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA
J.S. Rader	Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI, USA
R.H. Reeves	Department of Physiology, Johns Hopkins University, School of Medicine, Baltimore, MD, USA
K.L. Reichelt	Institute of Pediatric Research, The National Hospital, University of Oslo, Norway
T. Ried	Center for Cancer Research, Genetics Branch, NCI, NIH, Bethesda, MD, USA
G. Rimbach	Institute for Human Nutrition and Food Science, Christian-Albrechts-University, Kiel, Germany
K.D. Rodland	Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA, USA
C. Sansom	The School of Crystallography, Birbeck College, University of London, UK
N.A. Saunders	Centre for Immunology and Cancer Research, Princess Alexandra Hospital, University of Queensland, Australia
B.W. Schäfer	Department of Oncology, University Children's Hospital, Zurich, Switzerland
J. Schneider	Universidad Rey Juan Carlos, Facultad de Ciencias de la Salud, Alcorcón (Madrid), Spain
O.J. Semmes	Department of Microbiology and Molecular Cell Biology, Eastern Virginia Medical School, Norfolk, VA, USA
G.V. Sherbet	University of Newcastle, Merz Court, Department of Electrical and Electronic Engineering, Newcastle-upon-Tyne, UK
S. Smith	City of Hope Cancer Center, Department of Cell and Tumor Biology, Duarte, CA, USA
J.C. Strefford	Cancer Science Division, Southampton General Hospital, Southampton, UK
J.M. Trent	Tgen, Phoenix, AZ, USA
G. Tsangaris	Foundation of Biomedical Research of the Academy of Athens, Central Unit of Genomics-Proteomics, Athens, Greece
L.-C. Tsui	University of Hong Kong, Hong Kong
G.F. Vande Woude	Laboratory of Molecular Oncology, Van Andel Institute, Grand Rapids, MI, USA
D.K. Watson	Department of Pathology & Laboratory Medicine, The James E. Clyburn Research Center, Medical University of South Carolina, Charleston, SC, USA
U.H. Weidle	Roche Pharma Research and Early Development (pRED), Roche Diagnostics GmbH, Penzberg, Germany
A.T. Yeung	Fox Chase Cancer Center, Philadelphia, PA, USA
H. Zhang	Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, CT, USA

Articles in CANCER GENOMICS & PROTEOMICS are regularly indexed in the following bibliographic services: PUBMED, MEDLINE, CAS (Chemical Abstracts Service); BIOLOGICAL ABSTRACTS; EMBASE and BIOBASE; Compendex, GEOBASE; EMBiology; FLUIDEX; Scopus (Elsevier Bibliographic Databases); BIOSIS PREVIEWS; Science Citation Index Expanded (Web of Science); Google Scholar; LEEDS MEDICAL INFORMATION; CSA ILLUMINA (Cambridge Scientific Abstracts, including: Oncogenes & Growth Factors, Genetics, Medical & Pharmaceutical Biotechnology, Bioengineering); All-Russian Institute of Scientific and Technical Information – VINITI Abstracts Journal; PubsHub; Sociedad Iberoamericana de Información Científica (SIIC) Data Bases.

Editorial Office:

International Institute of Anticancer Research
 1st km Kapandritiou-Kalamou Road,
 P.O. Box 22, Kapandriti, Attiki, 19014, Greece.
 Tel: +30 22950 52945, Fax: +30 22950 53389
 e-mail: journals@iiar-anticancer.org. Web: www.iiar-anticancer.org; www.cgp.iiarjournals.org

Manuscripts and correspondence should be addressed to: Dr. John G. Delinasios, Managing Editor, Editorial Office, Cancer Genomics & Proteomics, 1st km Kapandritiou-Kalamou Road, P.O. Box 22, Kapandriti, Attiki, 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389, e-mail: editor@iiar-anticancer.org

Manuscripts from North America may be sent to the Editor-in-Chief, Prof. A. Seth, CGP, Laboratory of Molecular Pathology, Sunnybrook Research Institute, 2075 Bayview Avenue, Room S112a, Toronto, ON, Canada M4N 3M5. Fax: +1 416 480 5737, e-mail: genomics.proteomics@utoronto.ca

CANCER GENOMICS & PROTEOMICS

Volume 11, Number 3, May-June 2014

Contents

Crucial and Novel Cancer Drivers in a Mouse Model of Triple-negative Breast Cancer. J.P.S. JOHNSON, P. KUMAR, M. KOULNIS, M. PATEL, K. SIMIN (<i>Worcester, MA; Bethesda, MD; Scranton, PA, USA; Singapore</i>)	115
Profiling of Chromosomal Changes in Potentially Malignant and Malignant Oral Mucosal Lesions from South and South-East Asia Using Array-comparative Genomic Hybridization. M.L.S. LUNDE, E. ROMAN, S. WARNAKULASURIYA, R.I MEHROTRA, J. LARANNE, E.N. VASSTRAND, S.O. IBRAHIM (<i>Bergen, Norway; London, UK; Allahabad, India; Tampere, Finland</i>)	127
Target Genes of Recurrent Chromosomal Amplification and Deletion in Urothelial Carcinoma. M. WEILANDT, A. KOCH, H. RIEDER, R. DEENEN, H. SCHWENDER, G. NIEGISCHE, W.A. SCHULZ (<i>Düsseldorf, Germany</i>)	141
* Review: Structure and Role of WASP and WAVE in Rho GTPase Signalling in Cancer. J. LANE, T. MARTIN, H.P. WEEKS, W.G. JIANG (<i>Cardiff, UK</i>)	155

Instructions to Authors 2014

General Policy. CANCER GENOMICS & PROTEOMICS (CGP) welcomes the submission of high quality original articles and reviews on all aspects of the application of genomic and proteomic technologies to experimental and clinical cancer research. The journal's scientific spectrum includes: (a) molecular causes of carcinogenesis, cancer progression and metastasis; (b) structural and functional aspects of genes in the cancer cell; (c) advances in genomic and proteomic technologies applicable to cancer research; (d) rational anticancer drug design and drug development. CGP will also accept abstracts and proceedings of scientific meetings for publication, following consideration and approval by the Editorial Board.

The principal aim of CGP is to provide for the prompt online publication of original works of high quality, generally within 1-2 months of final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works that are not under consideration for publication by another journal (print or online), and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to CGP will be subject to peer-review by two members of the Editorial Board and by one suitable outside referee. All manuscripts submitted to CGP are urgently treated with absolute confidence, with access restricted to the Editor-in-Chief, the Managing Editor, the journal's secretary, the reviewers and the printers. The Editors reserve the right to improve manuscripts in terms of grammar and style.

The Editors and Publishers of CGP accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrantee due diligence in the creation and issuance of their work.

Open Access Policy. CGP appears bimonthly as an online-only open access journal through the Stanford University HighWire Press. Upon acceptance, Authors will be asked to pay an online publication fee of Euro 500.00 for articles up to 8 online pages (including figures and tables). Each additional excess page will be charged Euro 50.00. Color will not be charged. Authors from developing countries may apply for a 25% discount after the acceptance of their paper. CGP online will keep the volume and issue numbers, as well as page numbering.

Copyright. Authors retain copyright. The unrestricted *non-commercial* use, distribution and reproduction in any medium of CGP articles for academic reasons is allowed, provided that the original work is properly cited. The Authors grant the permanent right to the publisher to use any articles published in this journal without any restriction, including academic advertising purposes. PDF, XML and HTML files of all articles published in CGP are the property of the publisher.

Format. Two types of papers may be submitted: (i) full papers containing completed original work, and (ii) review articles concerning fields of recognizable progress. Papers should contain all the essential data in order to make the presentation clear. Papers should be written in clear, concise English. Spelling should follow that of the "Oxford English Dictionary".

Manuscripts. All manuscripts should be divided into the following sections: (a) *First page* including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) *Abstract* not exceeding 150 words, organized according to the following headings: Background - Materials and Methods or Patients and Methods - Results - Conclusion; (c) *Introduction*; (d) *Materials and Methods* or *Patients and Methods*; (e) *Results*; (f) *Discussion*; (g) *Acknowledgements* and (h) *References*. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's preference. Review articles should not exceed 35 pages (approximately 250 words per double-spaced page) including all tables, figures and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, at the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated on the reverse side. Color will not be charged.

Tables. Each table should be submitted on a separate page, double-spaced. Tables should be numbered with Roman numerals and should include a short title.

References. Authors must assume responsibility for the accuracy of the references used. Citations for the reference section of submitted works should follow the standard form of "Index Medicus" and must be numbered consecutively in the order that they appear in the text. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. *Anticancer Res 1*: 205-216, 1981. 2. McGuire WL and Chamness GC: Studies on the oestrogen receptor in breast cancer. *In: Receptors for Reproductive Hormones.* O' Malley BW and Chamness GC (eds.). New York, Plenum Publ Corp, pp.133-136, 1973. In the text, references should be denoted as: (1), (2-5), (6, 7) *etc.*

Nomenclature and Abbreviations. Nomenclature should follow that given in "Chemical Abstracts", "Index Medicus", "Merck Index", "IUPAC -IUB", "Bergey's Manual of Determinative Bacteriology", The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (<http://www.gene.ucl.ac.uk/>). Approved mouse nomenclature may be obtained from <http://www.informatics.jax.org/>. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text. For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by 'ISRCTN'). Please note that there is no space between the prefix 'ISRCTN' and the number. Example: ISRCTN47956475. For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

Ethical Policies and Standards. CGP agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard". Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Manuscripts may be submitted online (<http://www.iar-anticancer.org/submission/login.php>), via e-mail (journals@iar-anticancer.org), or by mail (3 complete copies plus, USB stick, DVD, CD or floppy disk) to the Editorial Office.

Editorial Office: International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki 19014, Greece. Tel / Fax: +30-22950-53389. E-mails: Editorial Office: journals@iar-anticancer.org. Managing Editor: editor@iar-anticancer.org

Galley Proofs. Galley proofs will be sent by e-mail to the corresponding Author. Corrections of galley proofs should be limited to typographical errors.